Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an announcement.
Atomo Diagnostics has updated its disclosure to the ASX regarding a proposed issue of securities under a securities purchase plan, clarifying compliance with ASX Guidance Note 30 and the Corporations Act. The company confirmed that shares offered under the SPP prospectus will be applied for quotation on the ASX and that associated SPP options will expire on 15 November 2028, 2.5 years from their proposed issue date.
The update replaces details in a previous March 30, 2026 announcement and reinforces Atomo’s adherence to regulatory requirements governing capital raisings and secondary market trading. By formalizing the quotation application and option expiry terms, the company provides greater certainty to investors and stakeholders around the structure and timing of the SPP securities, which may influence participation and market perception of the offering.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. is an Australian-listed medical diagnostics company focused on developing and supplying rapid test solutions. Its securities trade on the ASX under the code AT1, and it raises capital through placements and securities purchase plans to support its operations and growth initiatives.
Average Trading Volume: 2,349,202
Technical Sentiment Signal: Hold
Current Market Cap: A$25.23M
For an in-depth examination of AT1 stock, go to TipRanks’ Overview page.